Search Results for keywords:"Controlled Substances Act"

The Drug Enforcement Administration (DEA) has revoked the Certificate of Registration of James T. Craig, D.D.S., a dentist from Colorado, meaning he can no longer handle controlled substances. This decision was made because his dental license in Colorado was revoked, and he lacked the necessary state authority to dispense controlled substances. The DEA notified Craig of his right to a hearing, which he opted not to request, resulting in an automatic admission of the allegations against him. Consequently, any pending applications from Craig to renew or modify his registration have also been denied.

The Department of Justice's Drug Enforcement Administration (DEA) is seeking public comments on a new information collection proposal. They aim to revise existing forms (DEA Forms 224 and 224A) to include emergency medical services (EMS) agencies under the Controlled Substances Act. This change would allow EMS agencies to register to handle controlled substances in line with state law. The comment period is open for 30 days, during which people can share their thoughts on the proposal's necessity, accuracy, and possible burden on those required to respond.

The Drug Enforcement Administration (DEA) has revoked the DEA registration of Xubex Community Pharmacy in Casselberry, Florida. This decision was made because the pharmacy dispensed controlled substances, specifically Schedule II drugs like oxycodone and hydromorphone, without prescriptions. The DEA considered these actions a threat to public health and safety, demonstrating that the pharmacy cannot be trusted to comply with legal requirements. Furthermore, the pharmacy did not request a hearing to dispute these conclusions, leading to the default revocation of its registration.

The Drug Enforcement Administration (DEA) has issued a final order establishing the adjusted 2024 aggregate production quotas for Schedule I and II controlled substances under the Controlled Substances Act, and the annual needs for certain list I chemicals like ephedrine. This decision was made after considering public comments and relevant factors such as production needs, diversion risks, and quotas set in prior years. DEA strives to ensure that these quotas meet lawful medical and scientific needs while preventing drug misuse. Some public suggestions, like changes to the procurement quota processes or addressing opioid shortage concerns, were noted but found to be outside the scope of this specific order.

The Department of Justice, specifically the Drug Enforcement Administration (DEA), is requesting public feedback on a proposed information collection related to emergency medical services and controlled substances. This proposal aims to ensure compliance with the Controlled Substances Act by setting new recordkeeping standards for emergency medical services agencies. These standards involve maintaining records of controlled substances used by these agencies, which include details about administration, disposal, and delivery. The DEA encourages comments on the necessity, burden, and clarity of this information collection until January 13, 2025, as part of their efforts to secure approval for a three-year authorization under the Paperwork Reduction Act.

The Drug Enforcement Administration (DEA) has decided to revoke Dr. Yogesh Patel's DEA registration because he is not permitted to handle controlled substances as he lacks the authority to practice medicine in Colorado. The DEA's Order to Show Cause indicated that Dr. Patel's Colorado medical license is restricted, preventing him from practicing medicine, which is a critical requirement for maintaining his DEA registration. Dr. Patel did not request a hearing or dispute these allegations, leading to the revocation of his registration and denial of any pending applications. This decision was finalized by Acting Administrator Derek Maltz and will take effect on March 17, 2025.

The Drug Enforcement Administration (DEA) is extending the temporary Schedule I classification for seven specific fentanyl-related substances. This extension lasts for one year or until a permanent decision is made. These substances are considered a public safety hazard, and the DEA is working on permanently scheduling them. The temporary classification does not require the normal rulemaking processes, as the DEA needs to act quickly to prevent potential dangers.

In the Federal Register notice titled "Ibrahim Al-Qawaqneh, D.D.S.; Decision and Order," the DEA sought to revoke Dr. Ibrahim Al-Qawaqneh's registration due to his exclusion from federal health care programs after pleading nolo contendere to a charge of offering unlawful Medi-Cal remuneration. Despite being given a chance to defend himself, the DEA found that Dr. Al-Qawaqneh failed to take full responsibility for his actions, which led to doubts about his trustworthiness. Consequently, his DEA Certificate of Registration was revoked to ensure compliance with laws regulating controlled substances.

The Drug Enforcement Administration (DEA) and the Department of Health and Human Services (HHS) have finalized a rule expanding the ability for practitioners to prescribe certain controlled substances for opioid use disorder (OUD) treatment through telemedicine, including audio-only calls. Under these new rules, practitioners can prescribe a six-month supply of these medications after reviewing the patient's prescription drug monitoring program data, with the possibility of extending prescriptions through telemedicine or after a face-to-face evaluation. Additional safeguards include identity verification by pharmacists before filling prescriptions to prevent misuse. The rule aims to continue the telemedicine flexibilities introduced during the COVID-19 pandemic while addressing the opioid crisis and concerns about substance misuse.

The Drug Enforcement Administration (DEA) has decided to revoke the registration of Jeffrey W. Young, Jr., a nurse practitioner from Tennessee, due to his lack of state authorization to handle controlled substances. Young's Tennessee nurse and advanced practice nurse licenses were both revoked, making him ineligible to dispense medications under state laws. Despite being given a chance, Young did not request a hearing to challenge this decision, leading the DEA to proceed with the revocation of his Certificate of Registration. This order will be effective from January 29, 2025.